Latest Healthcare News

Immuron Limited has launched PROIBS®, a new medical device aimed at relieving symptoms of Irritable Bowel Syndrome (IBS), entering a growing Australian market with strong early demand.

AdAlta Limited has fully repaid its remaining NLSC investment in cash, ending its obligation to issue further shares and positioning itself for private capital raises to advance its CAR-T therapies.

Memphasys secures a follow-up order for its Felix™ sperm selection cartridges from a leading Japanese fertility clinic, marking growing adoption in one of the world’s largest IVF markets and signaling a strategic shift to direct sales.

Vitasora Health is set to scale its AI-powered chronic care services from Hawaii to 10-15 US states, leveraging a new partnership with Privia Health following Evolent Care Partners' divestiture. This expansion targets up to 30,000 patients and promises significant revenue growth in 2026.

Regis Healthcare has agreed to acquire two modern aged care homes on Victoria’s Surf Coast and Bellarine Peninsula, adding 230 beds and boosting its portfolio to 74 homes. The $45 million deal is expected to be earnings accretive by FY26.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.